Straumann Holding AG (OTCMKTS:SAUHY) Sees Large Decline in Short Interest

by · The Cerbat Gem

Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totaling 26,983 shares, a decline of 39.9% from the September 30th total of 44,911 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 255,560 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

SAUHY has been the subject of a number of recent analyst reports. UBS Group raised Straumann from a “neutral” rating to a “buy” rating in a report on Tuesday, September 1st. Berenberg Bank upgraded Straumann to a “strong-buy” rating in a research report on Thursday, September 17th. The Goldman Sachs Group raised Straumann from a “neutral” rating to a “buy” rating in a research note on Monday, September 14th. Deutsche Bank Aktiengesellschaft lowered Straumann from a “buy” rating to a “hold” rating in a report on Friday, August 21st. Finally, Citigroup restated a “sell” rating on shares of Straumann in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Get Our Latest Report on SAUHY

Straumann Trading Up 3.6%

Straumann stock opened at $12.21 on Tuesday. Straumann has a 12-month low of $9.44 and a 12-month high of $13.61. The firm has a 50 day simple moving average of $11.43 and a 200-day simple moving average of $11.66.

About Straumann

(Get Free Report)

Straumann Group is a Switzerland-based dental technology company headquartered in Basel. Founded in 1954, the company develops, manufactures and distributes products used in tooth replacement, restorative dentistry and oral tissue regeneration. Its offerings are designed for dental professionals, laboratories and patients across a range of clinical applications.

The company’s portfolio includes dental implants, implant-supported prosthetics, biomaterials for bone and tissue regeneration, orthodontic aligners and digital dentistry solutions.

Featured Stories